Monoamine transporters (MATs) are protein structures that function as integral plasma-membrane transporters to regulate concentrations of extracellular monoamine neurotransmitters. Three major classes of MATs (SERT, DAT, NET) are responsible for the reuptake of their associated amine neurotransmitters (serotonin, dopamine, norepinephrine). MATs are located just outside the synaptic cleft (peri-synaptically), transporting monoamine transmitter overflow from the synaptic cleft back to the cytoplasm of the pre-synaptic neuron. MAT regulation generally occurs throughphosphorylation and posttranslational modification. Due to their significance in neuronal signaling, MATs are commonly associated with drugs used to treat mental disorders as well as recreational drugs. Compounds targeting MATs range from medications such as the wide variety of tricyclic antidepressants, selective serotonin reuptake inhibitors to stimulantmedications and amphetamine.
Cat. No. | Product Name | CAS No. | Information |
---|---|---|---|
H6770 |
Valbenazine |
1025504-45-3 | A novel, highly selective vesicular monoamine transporter 2 (VMAT2) inhibitor; is approved for the treatment of tardive dyskinesia. |
H4555 |
Vanoxerine dihydrochloride |
67469-78-7 | Vanoxerine (GBR-12909, I-893) is a highly potent inhibitor of dopamine uptake in vitro in tissue slices obtained from rat neostriatum with IC50 of 40-50 nM, also inhibits norepinephrine uptake with IC50 of 560-2600 nM; Vanoxerine also is a potent hK(v)11.1 blocker, and at submicromolar concentrations, it blocks Ca and Na currents in a strongly frequency-dependent manner possesses anticonvulsant activity in zebrafish and rodent models of generalized epilepsy but with cardiac ion channel effects. |
H4554 |
Vanoxerine |
67469-69-6 | Vanoxerine (GBR-12909, I-893, Boxeprazine) is a highly potent inhibitor of dopamine uptake in vitro in tissue slices obtained from rat neostriatum with IC50 of 40-50 nM, also inhibits norepinephrine uptake with IC50 of 560-2600 nM; Vanoxerine also is a potent hK(v)11.1 blocker, and at submicromolar concentrations, it blocks Ca and Na currents in a strongly frequency-dependent manner possesses anticonvulsant activity in zebrafish and rodent models of generalized epilepsy but with cardiac ion channel effects. |
H4553 |
SRI-31142 |
1940118-04-6 | SRI-31142 (SRI31142) is a novel potent, putative allosteric dopamine transporter (DAT) inhibitor with Ki of 1.9 nM. |
H4552 |
Solriamfetol hydrochloride |
178429-62-4 |
Solriamfetol hydrochloride (JZP-110, R-228060, ADX-N05, YKP-10A)?is a norepinephrine-dopamine reuptake inhibitor that inhibits dopamine and norepinephrine transporter with IC50 of 2.9 and 4.4 uM, respectively; a wake-promoting agent with dopaminergic and noradrenergic activity. |
H4551 |
Serdexmethylphenidate |
1996626-29-9 | Serdexmethylphenidate is the dextrorotary form of methylphenidate and a norepinephrine-dopamine reuptake inhibitor (NDRI) and thus a psychostimulant. |
H4550 |
Radafaxine hydrochloride |
106083-71-0 | A potent metabolite of bupropion; selectivly inhibits the reuptake of norepinephrine over dopamine; DAT and NET transporters inhibitor, and nAChR family modulator. |
H4549 |
PF-184298 |
813447-40-4 | PF-184298 is a potent, selective dual serotonin and noradrenaline monoamine reuptake inhibitor (SNRI) with IC50 of 6 nM and 21 nM, respectively; displays good selectivity over dopamine reuptake inhibition (DRI) (IC50=544 nM); possesses good in vitro metabolic stability, weak CYP inhibition and drug-like physicochemical properties consistent with CNS target space. |
H4548 |
Paroxetine hydrochloride hemihydrate |
110429-35-1 | An antidepressant of the selective serotonin reuptake inhibitor (SSRI) class; also shows to be a selective inhibitor of GRK2 activity both in vitro and in living cells; induce autophagy dependent-NLRP3-inflammasome inhibition in Major depressive disorder. |
H4547 |
Paroxetine hydrochloride |
78246-49-8 | An antidepressant of the selective serotonin reuptake inhibitor (SSRI) class; also shows to be a selective inhibitor of GRK2 activity both in vitro and in living cells; induce autophagy dependent-NLRP3-inflammasome inhibition in Major depressive disorder. |
086-18516630705
sales@hmobio.com
1/F, building 4, No. 358-368, Kefu Road, Jiading District, Shanghai, China